- Home
- Publications
- Publication Search
- Publication Details
Title
Complement as a Biological Tool to Control Tumor Growth
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-09-25
DOI
10.3389/fimmu.2018.02203
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD59: a promising target for tumor immunotherapy
- (2018) Ronghua Zhang et al. Future Oncology
- Targeting complement-mediated immunoregulation for cancer immunotherapy
- (2018) Martin Kolev et al. SEMINARS IN IMMUNOLOGY
- Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
- (2018) Aurélie Durgeau et al. Frontiers in Immunology
- Unraveling the Role of Angiogenesis in Cancer Ecosystems
- (2018) Iratxe Zuazo-Gaztelu et al. Frontiers in Oncology
- Beyond the Role of CD55 as a Complement Component
- (2018) So Hee Dho et al. Immune Network
- In Vivo Biodistribution and Lifetime Analysis of Cy5.5-Conjugated Rituximab in Mice Bearing Lymphoid Tumor Xenograft Using Time-Domain Near-Infrared Optical Imaging
- (2018) Stefania Biffi et al. Molecular Imaging
- The complement system in cancer: Ambivalence between tumour destruction and promotion
- (2017) Srinivas Mamidi et al. IMMUNOBIOLOGY
- A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo
- (2017) Mohit K. Verma et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms
- (2017) Kirstie L. S. Cleary et al. JOURNAL OF IMMUNOLOGY
- Complement as a regulator of adaptive immunity
- (2017) Justin Killick et al. Seminars in Immunopathology
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
- (2017) Michael J. E. Marshall et al. Frontiers in Immunology
- New perspectives on complement mediated immunotherapy
- (2016) Grzegorz Stasiłojć et al. CANCER TREATMENT REVIEWS
- Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors
- (2016) Satish Kumar Devarapu et al. INTERNATIONAL JOURNAL OF CANCER
- Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions
- (2016) Erika M. Cook et al. JOURNAL OF IMMUNOLOGY
- Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells
- (2016) Margaret A. Lindorfer et al. MOLECULAR IMMUNOLOGY
- Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
- (2016) Ronald P. Taylor et al. SEMINARS IN IMMUNOLOGY
- C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation
- (2016) Roberta Bulla et al. Nature Communications
- The High Prevalence of Functional Complement Defects Induced by Chemotherapy
- (2016) Mischa P. Keizer et al. Frontiers in Immunology
- Dinutuximab: First Global Approval
- (2015) Sohita Dhillon DRUGS
- Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical Response
- (2015) Laura Surace et al. IMMUNITY
- Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue
- (2015) T.A.M. Bouwens et al. JOURNAL OF NEUROIMMUNOLOGY
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles
- (2015) Sara Capolla et al. Nano Research
- Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review)
- (2015) MARIANA DÍAZ-ZARAGOZA et al. ONCOLOGY REPORTS
- Complement System Part I – Molecular Mechanisms of Activation and Regulation
- (2015) Nicolas S. Merle et al. Frontiers in Immunology
- Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche
- (2014) S. K. Vadrevu et al. CANCER RESEARCH
- Complement in Antibody-Based Tumor Therapy
- (2014) Stefanie Derer et al. CRITICAL REVIEWS IN IMMUNOLOGY
- The extracellular matrix modulates the hallmarks of cancer
- (2014) M. W. Pickup et al. EMBO REPORTS
- Mortalin/GRP75 Binds to Complement C9 and Plays a Role in Resistance to Complement-dependent Cytotoxicity
- (2014) Moran Saar Ray et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice
- (2014) P Macor et al. LEUKEMIA
- Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness
- (2014) HIDETOSHI NITTA et al. ONCOLOGY REPORTS
- Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
- (2014) C. A. Diebolder et al. SCIENCE
- Complement-Dependent Modulation of Antitumor Immunity following Radiation Therapy
- (2014) Michelle Elvington et al. Cell Reports
- Autocrine Effects of Tumor-Derived Complement
- (2014) Min Soon Cho et al. Cell Reports
- The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation
- (2013) K. Triantafilou et al. JOURNAL OF CELL SCIENCE
- Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
- (2013) Srinivas Mamidi et al. Molecular Oncology
- New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles
- (2013) Nelly Mezzaroba et al. PLoS One
- Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice
- (2013) Silvio Bandini et al. OncoImmunology
- Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression
- (2012) Leticia Corrales et al. JOURNAL OF IMMUNOLOGY
- Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
- (2012) F. J. Beurskens et al. JOURNAL OF IMMUNOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
- (2011) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- CD46 Expression is an Unfavorable Prognostic Factor in Breast Cancer Cases
- (2011) Adam Maciejczyk et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
- (2010) A Michlmayr et al. BRITISH JOURNAL OF CANCER
- The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
- (2010) Dietmar W. Siemann CANCER TREATMENT REVIEWS
- Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia
- (2010) Wei Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
- (2010) Yi-Fan Hsu et al. Molecular Cancer
- Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma
- (2009) Abraham Klepfish et al. Annals of the New York Academy of Sciences
- In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
- (2009) K El-Sahwi et al. BRITISH JOURNAL OF CANCER
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Natural antibodies and cancer
- (2009) H. Peter Vollmers et al. New Biotechnology
- Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells
- (2009) Chen ONCOLOGY REPORTS
- Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
- (2008) M. Dechant et al. CANCER RESEARCH
- Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
- (2008) Clive S. Zent et al. LEUKEMIA RESEARCH
- Modulation of the antitumor immune response by complement
- (2008) Maciej M Markiewski et al. NATURE IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started